Natural Anticancer Compounds and Their Derivatives in Clinical Trials

Veerabhadrappa, Bhavana; Sudharshan, S. J.; Madhu, Dyavaiah

doi:10.1007/978-981-10-8216-0_3

Cited by 7 publications

(6 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nature has provided us with many substances displaying anticancer activity which have widely been applied in medicine, such as taxanes, vinca alkaloids, podophyllotoxin, camptothecin, anthracyclines, their derivatives and others [340]. In recent years, a vast number of natural compounds have been tested to establish their medical potential in cancer therapy [341]; however, only a small minority of these substances have qualified for clinical trials and treatment of cancer patients [26]. In recent years, polyphenols, (mostly green tea catechins) were investigated in patients suffering from prostate cancer; however, the collected data suggested that the action of the compounds was not directly aimed at cancer prevention [342].…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, continued study using in vivo systems and improved clinical trials are necessary to establish the safety and clinical application of nature-derived medicines. Moreover, it is essential to use high-throughput drug screening technology such as NMR (nuclear magnetic resonance spectrometry), LC-MS (liquid chromatography-mass spectrometry), HPLC-MS (high-performance liquid chromatography-mass spectrometry) and others, to find new natural substances for forthcoming research [341]. Natural compounds remain an interesting tool in cancer treatment, thus we believe that more promising anticancer substances will be discovered which will allow for untapped scientific possibilities.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

In Search of Panacea—Review of Recent Studies Concerning Nature-Derived Anticancer Agents

et al. 2019

View full text Add to dashboard Cite

Cancers are one of the leading causes of deaths affecting millions of people around the world, therefore they are currently a major public health problem. The treatment of cancer is based on surgical resection, radiotherapy, chemotherapy or immunotherapy, much of which is often insufficient and cause serious, burdensome and undesirable side effects. For many years, assorted secondary metabolites derived from plants have been used as antitumor agents. Recently, researchers have discovered a large number of new natural substances which can effectively interfere with cancer cells’ metabolism. The most famous groups of these compounds are topoisomerase and mitotic inhibitors. The aim of the latest research is to characterize natural compounds found in many common foods, especially by means of their abilities to regulate cell cycle, growth and differentiation, as well as epigenetic modulation. In this paper, we focus on a review of recent discoveries regarding nature-derived anticancer agents.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

In Search of Panacea—Review of Recent Studies Concerning Nature-Derived Anticancer Agents

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, only 15–20% of tumors can be radically resected, because the tumor is not always clearly identifiable. During surgery, the lobe or the section of the lung containing the tumor is removed, using imaging techniques such as video-assisted thoracoscopic surgery (VATS) and biopsies as support [ 41 , 42 , 43 , 44 , 45 ]. Typically, surgery is combined with radiation therapy sessions as a neoadjuvant to decrease the size of the tumor, confine it to a specific body region, and facilitate its resection.…”

Section: Conventional Treatmentsmentioning

confidence: 99%

Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy

García-Fernández

Fornaguera

Borrós

2020

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.

show abstract

“…Many chemotherapeutic agents used in clinical practice are developed from natural compounds or their derivatives and analogs, e.g., etoposide, eribulin, paclitaxel, vincristine, vinblastine, topotecan, cytarabine, doxorubicin, dactinomycin, and bleomycin [ 3 , 4 , 5 ]. These also include medicines developed and introduced into clinical practice from the 1950s–1960s (vincristine, vinblastine, cytarabine, etc.…”

Section: Introductionmentioning

confidence: 99%

“…), as well as modern agents developed in the 2000’s (topotecan, eribulin). Many chemotherapeutic agents based on natural analogs continue to undergo clinical studies to evaluate their effectiveness in the treatment of various types of tumors, as drugs developed from natural compounds often show lower toxicity and have higher target values towards malignant tumor cells [ 3 ]. While scientists continue to research these compounds, these naturally derived drugs are already relevant in the market today, with close to 40% of antitumor drugs approved by the FDA being of natural origin or semi-synthetic derivatives of natural compounds.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Biological Evaluation of Phaeosphaeride A Derivatives as Antitumor Agents

et al. 2018

View full text Add to dashboard Cite

New derivatives of phaeosphaeride A (PPA) were synthesized and characterized. Anti-tumor activity studies were carried out on the HCT-116, PC3, MCF-7, A549, К562, NCI-Н929, Jurkat, THP-1, RPMI8228 tumor cell lines, and on the HEF cell line. All of the compounds synthesized were found to have better efficacy than PPA towards the tumor cell lines mentioned. Compound 6 was potent against six cancer cell lines, HCT-116, PC-3, K562, NCI-H929, Jurkat, and RPMI8226, showing a 47, 13.5, 16, 4, 1.5, and 7-fold increase in anticancer activity comparative to those of etoposide, respectively. Compound 1 possessed selectivity toward the NCI-H929 cell line (IC50 = 1.35 ± 0.69 μM), while product 7 was selective against three cancer cell lines, HCT-116, MCF-7, and NCI-H929, each having IC50 values of 1.65 μM, 1.80 μM and 2.00 μM, respectively.

show abstract

Natural Anticancer Compounds and Their Derivatives in Clinical Trials

Cited by 7 publications

References 141 publications

In Search of Panacea—Review of Recent Studies Concerning Nature-Derived Anticancer Agents

In Search of Panacea—Review of Recent Studies Concerning Nature-Derived Anticancer Agents

Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy

Synthesis and Biological Evaluation of Phaeosphaeride A Derivatives as Antitumor Agents

Contact Info

Product

Resources

About